Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23

Xijie Yu, Omar A. Ibrahimi, Regina Goetz, Fuming Zhang, Siobhan I. Davis, Holly Garringer, Robert J. Linhardt, David M. Ornitz, Moosa Mohammadi, Kenneth White

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Fibroblast growth factor (FGF)-23 has emerged as an endocrine regulator of phosphate and of vitamin D metabolism. It is produced in bone and, unlike other FGFs, circulates in the bloodstream to ultimately regulate phosphate handling and vitamin D production in the kidney. Presently, it is unknown which of the seven principal FGF receptors (FGFRs) transmits FGF23 biological activity. Furthermore, the molecular basis for the endocrine mode of FGF23 action is unclear. Herein, we performed surface plasmon resonance and mitogenesis experiments to comprehensively characterize receptor binding specificity. Our data demonstrate that FGF23 binds and activates the c splice isoforms of FGFR1-3, as well as FGFR4, but not the b splice isoforms of FGFR1-3. Interestingly, highly sulfated and longer glycosaminoglycan (GAG) species were capable of promoting FGF23 mitogenic activity. We also show that FGF23 induces tyrosine phosphorylation and inhibits sodium-phosphate cotransporter Npt2a mRNA expression using opossum kidney cells, a model kidney proximal tubule cell line. Removal of cell surface GAGs abolishes the effects of FGF23, and exogenous highly sulfated GAG is capable of restoring FGF23 activity, suggesting that proximal tubule cells naturally express GAGs that are permissive for FGF23 action. We propose that FGF23 signals through multiple FGFRs and that the unique endocrine actions of FGF23 involve escape from FGF23-producing cells and circulation to the kidney, where highly sulfated GAGs most likely act as cofactors for FGF23 activity. Our biochemical findings provide important insights into the molecular mechanisms by which dysregulated FGF23 signaling leads to disorders of hyper- and hypophosphatemia.

Original languageEnglish
Pages (from-to)4647-4656
Number of pages10
JournalEndocrinology
Volume146
Issue number11
DOIs
StatePublished - Nov 2005

Fingerprint

A73025
Fibroblast Growth Factor Receptors
Vitamin D
Protein Isoforms
Sodium-Phosphate Cotransporter Proteins
Phosphates
Hyperphosphatemia
Hypophosphatemia
Kidney
Opossums
Proximal Kidney Tubule
Surface Plasmon Resonance
Renal Circulation
Tyrosine
Phosphorylation
Bone and Bones
Cell Line
Messenger RNA
fibroblast growth factor 23

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. / Yu, Xijie; Ibrahimi, Omar A.; Goetz, Regina; Zhang, Fuming; Davis, Siobhan I.; Garringer, Holly; Linhardt, Robert J.; Ornitz, David M.; Mohammadi, Moosa; White, Kenneth.

In: Endocrinology, Vol. 146, No. 11, 11.2005, p. 4647-4656.

Research output: Contribution to journalArticle

Yu, X, Ibrahimi, OA, Goetz, R, Zhang, F, Davis, SI, Garringer, H, Linhardt, RJ, Ornitz, DM, Mohammadi, M & White, K 2005, 'Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23', Endocrinology, vol. 146, no. 11, pp. 4647-4656. https://doi.org/10.1210/en.2005-0670
Yu, Xijie ; Ibrahimi, Omar A. ; Goetz, Regina ; Zhang, Fuming ; Davis, Siobhan I. ; Garringer, Holly ; Linhardt, Robert J. ; Ornitz, David M. ; Mohammadi, Moosa ; White, Kenneth. / Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. In: Endocrinology. 2005 ; Vol. 146, No. 11. pp. 4647-4656.
@article{2ef493470ab54405a6a11fb0d6327e27,
title = "Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23",
abstract = "Fibroblast growth factor (FGF)-23 has emerged as an endocrine regulator of phosphate and of vitamin D metabolism. It is produced in bone and, unlike other FGFs, circulates in the bloodstream to ultimately regulate phosphate handling and vitamin D production in the kidney. Presently, it is unknown which of the seven principal FGF receptors (FGFRs) transmits FGF23 biological activity. Furthermore, the molecular basis for the endocrine mode of FGF23 action is unclear. Herein, we performed surface plasmon resonance and mitogenesis experiments to comprehensively characterize receptor binding specificity. Our data demonstrate that FGF23 binds and activates the c splice isoforms of FGFR1-3, as well as FGFR4, but not the b splice isoforms of FGFR1-3. Interestingly, highly sulfated and longer glycosaminoglycan (GAG) species were capable of promoting FGF23 mitogenic activity. We also show that FGF23 induces tyrosine phosphorylation and inhibits sodium-phosphate cotransporter Npt2a mRNA expression using opossum kidney cells, a model kidney proximal tubule cell line. Removal of cell surface GAGs abolishes the effects of FGF23, and exogenous highly sulfated GAG is capable of restoring FGF23 activity, suggesting that proximal tubule cells naturally express GAGs that are permissive for FGF23 action. We propose that FGF23 signals through multiple FGFRs and that the unique endocrine actions of FGF23 involve escape from FGF23-producing cells and circulation to the kidney, where highly sulfated GAGs most likely act as cofactors for FGF23 activity. Our biochemical findings provide important insights into the molecular mechanisms by which dysregulated FGF23 signaling leads to disorders of hyper- and hypophosphatemia.",
author = "Xijie Yu and Ibrahimi, {Omar A.} and Regina Goetz and Fuming Zhang and Davis, {Siobhan I.} and Holly Garringer and Linhardt, {Robert J.} and Ornitz, {David M.} and Moosa Mohammadi and Kenneth White",
year = "2005",
month = "11",
doi = "10.1210/en.2005-0670",
language = "English",
volume = "146",
pages = "4647--4656",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23

AU - Yu, Xijie

AU - Ibrahimi, Omar A.

AU - Goetz, Regina

AU - Zhang, Fuming

AU - Davis, Siobhan I.

AU - Garringer, Holly

AU - Linhardt, Robert J.

AU - Ornitz, David M.

AU - Mohammadi, Moosa

AU - White, Kenneth

PY - 2005/11

Y1 - 2005/11

N2 - Fibroblast growth factor (FGF)-23 has emerged as an endocrine regulator of phosphate and of vitamin D metabolism. It is produced in bone and, unlike other FGFs, circulates in the bloodstream to ultimately regulate phosphate handling and vitamin D production in the kidney. Presently, it is unknown which of the seven principal FGF receptors (FGFRs) transmits FGF23 biological activity. Furthermore, the molecular basis for the endocrine mode of FGF23 action is unclear. Herein, we performed surface plasmon resonance and mitogenesis experiments to comprehensively characterize receptor binding specificity. Our data demonstrate that FGF23 binds and activates the c splice isoforms of FGFR1-3, as well as FGFR4, but not the b splice isoforms of FGFR1-3. Interestingly, highly sulfated and longer glycosaminoglycan (GAG) species were capable of promoting FGF23 mitogenic activity. We also show that FGF23 induces tyrosine phosphorylation and inhibits sodium-phosphate cotransporter Npt2a mRNA expression using opossum kidney cells, a model kidney proximal tubule cell line. Removal of cell surface GAGs abolishes the effects of FGF23, and exogenous highly sulfated GAG is capable of restoring FGF23 activity, suggesting that proximal tubule cells naturally express GAGs that are permissive for FGF23 action. We propose that FGF23 signals through multiple FGFRs and that the unique endocrine actions of FGF23 involve escape from FGF23-producing cells and circulation to the kidney, where highly sulfated GAGs most likely act as cofactors for FGF23 activity. Our biochemical findings provide important insights into the molecular mechanisms by which dysregulated FGF23 signaling leads to disorders of hyper- and hypophosphatemia.

AB - Fibroblast growth factor (FGF)-23 has emerged as an endocrine regulator of phosphate and of vitamin D metabolism. It is produced in bone and, unlike other FGFs, circulates in the bloodstream to ultimately regulate phosphate handling and vitamin D production in the kidney. Presently, it is unknown which of the seven principal FGF receptors (FGFRs) transmits FGF23 biological activity. Furthermore, the molecular basis for the endocrine mode of FGF23 action is unclear. Herein, we performed surface plasmon resonance and mitogenesis experiments to comprehensively characterize receptor binding specificity. Our data demonstrate that FGF23 binds and activates the c splice isoforms of FGFR1-3, as well as FGFR4, but not the b splice isoforms of FGFR1-3. Interestingly, highly sulfated and longer glycosaminoglycan (GAG) species were capable of promoting FGF23 mitogenic activity. We also show that FGF23 induces tyrosine phosphorylation and inhibits sodium-phosphate cotransporter Npt2a mRNA expression using opossum kidney cells, a model kidney proximal tubule cell line. Removal of cell surface GAGs abolishes the effects of FGF23, and exogenous highly sulfated GAG is capable of restoring FGF23 activity, suggesting that proximal tubule cells naturally express GAGs that are permissive for FGF23 action. We propose that FGF23 signals through multiple FGFRs and that the unique endocrine actions of FGF23 involve escape from FGF23-producing cells and circulation to the kidney, where highly sulfated GAGs most likely act as cofactors for FGF23 activity. Our biochemical findings provide important insights into the molecular mechanisms by which dysregulated FGF23 signaling leads to disorders of hyper- and hypophosphatemia.

UR - http://www.scopus.com/inward/record.url?scp=26844564690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844564690&partnerID=8YFLogxK

U2 - 10.1210/en.2005-0670

DO - 10.1210/en.2005-0670

M3 - Article

C2 - 16081635

AN - SCOPUS:26844564690

VL - 146

SP - 4647

EP - 4656

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 11

ER -